All In Biotech

Drug Trial Radar · NCT06976476

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Prospective Randomized Phase II Study Evaluating Efficacy and Safety of IgPro20 as Infection Prophylaxis in Patients With Multiple Myeloma and Hypogammaglobulinemia Receiving Therapy With a Bispecific Monoclonal Antibody (BsAbs)

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

May 8, 2025

Primary completion

May 8, 2029

Study completion May 8, 2029

Sponsor

Lead sponsor
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).

Conditions

  • Multiple Myeloma
  • Hypogammaglobulinemia
  • Hypogammaglobulinemia, Acquired

Interventions

  • IgPro20Drug

    Will be administered in addition to Standard of Care treatment. IgPro20 is intended for subcutaneous administration using an infusion pump

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in overall infection rates between Standard of Care participants and participants receiving IgPro20Time frame: 6 months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Emory University (Data Collection Only)

    Atlanta, Georgia · Recruiting

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

    Basking Ridge, New Jersey · Recruiting

  • Memorial Sloan Kettering Monmouth (All Protocol Activities)

    Middletown, New Jersey · Recruiting

  • Memorial Sloan Kettering Bergen (All Protocol Activities)

    Montvale, New Jersey · Recruiting

  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activity)

    Commack, New York · Recruiting

  • Memorial Sloan Kettering Westchester (All Protocol Activities)

    Harrison, New York · Recruiting

  • Mount Sinai Hospital

    New York, New York · Not yet recruiting

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York · Recruiting

  • Memorial Sloan Kettering Nassau (All Protocol Activities)

    Uniondale, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.